Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeeing Machines Regulatory News (SEE)

Share Price Information for Seeing Machines (SEE)

Share Price is delayed by 15 minutes
Get Live Data
4.25    -0.06 (-1.39%)
Bid:
4.20
Ask:
4.25
Spread: 0.05 (1.19%)
Market Cap: £203.98m
SEE Live PriceLast checked at - London Stock Exchange

Intraday Seeing Machines Share Chart

Director & Senior Manager Share Awards

28 Apr 2011 13:44

RNS Number : 6633F
Seeing Machines Limited
28 April 2011
 



28 April 2011

 

 

SEEING MACHINES LIMITED

 

DIRECTOR & Senior Manager SHARE AWARDS

Seeing Machines Limited (AIM:SEE), a leading developer of advanced computer based imaging software systems announces that it has today issued 767,099 new fully paid ordinary shares ("New Ordinary Shares") to certain Directors and senior managers under the July 2010 Executive Share Plan which was approved at the Annual General Meeting in November 2010. All shares issued under the plan are based on a salary/fee sacrifice arrangement.

Under the plan the Directors' received shares as follows:

Director

Number of New Ordinary Shares

Holding following receipt of New Ordinary Shares

Percentage holding following receipt of New Ordinary Shares

Robert Charles Sale 1

120,724

5,487,808

1.34%

Nicholas John Cerneaz2

188,631

2,049,044

0.50%

David John Gaul 3

60,362

2,020,948

0.49%

Trent William Victor

60,362

236,236

0.06%

1. Robert Sales shares are 2,745,715 shares held in the name of Caffe Pty Ltd ATF the R C Sale Superannuation Fund, 2,621,369 shares held by Robert's wife Paula Kay Sale and 120,724 shares held in his own name.

2. Nicholas John Cerneaz holds 1,467,332 shares through Cenika Pty Ltd ATF Cenika Super Fund and 581,712 in his own name.

3. David Gaul holds 2,020,948 shares through his company Jaiclimb Pty Limited.

Under the Plan the following senior managers received shares as follows:

Senior Manager

Role

Number of New Ordinary Shares

Holding following receipt of New Ordinary Shares

Percentage holding following receipt of New Ordinary Shares

Belinda Burgess 4

COO & Company Secretary

186,116

2,401,550

0.59%

Timothy Edwards

Principal Engineer

75,452

21,681,316

5.30%

Sebastien Rougeaux

Principal Research Scientist

75,452

22,174,792

5.42%

4. Belinda Burgess holds 965,870 shares in her own name and 1,435,680 shares in the names Belinda Burgess and Jennifer Kruse as trustees for the Meg & Susie Super Fund.

Application has been made for the New Ordinary Shares to be admitted to trading on AIM. It is expected that admission will occur and that dealings will commence at 8.00 a.m. on 6 May 2011. Immediately following admission of the New Ordinary Shares, the Company will have 408,908,546 fully paid ordinary shares on issue.

 

Enquiries:

 

Seeing Machines Limited

Nick Cerneaz, CEO +61 (0) 2 6103 4700

Daniel Stewart & Company plc

Oliver Rigby +44 (0) 20 7776 6550

Walbrook PR Ltd

Bob Huxford +44 (0) 20 7933 8783

Helen Westaway +44 (0) 20 7933 8790

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSDMGZDZRZGMZM
Date   Source Headline
21st May 20097:58 amRNSDirector Shareholding
11th Mar 20097:00 amRNSReviewed Interim Results
18th Feb 20097:00 amRNSRestructuring of the business
28th Jan 20099:41 amRNSTrading update and notice of results
1st Dec 20088:14 amRNSChange of Registered Office
27th Nov 20088:08 amRNSResult of AGM
29th Oct 200810:52 amRNSNotice of AGM
23rd Sep 20087:00 amRNSFinal Results
17th Sep 20088:37 amRNSNotice of Final Results
26th Aug 20088:33 amRNSNEW FACEAPI PRODUCT RELEASE
23rd Jul 20087:37 amRNSFirst Expected Profit Report
7th May 20088:08 amRNSNORTH AMERICAN OPERATION
7th Apr 200812:00 pmRNSChange of Broker
4th Mar 20087:59 amRNSInterim Results
4th Mar 20087:51 amRNSMajor contract gain
13th Feb 20088:27 amRNSHolding in Company
28th Dec 20079:11 amRNSAnnual Report
11th Dec 200710:54 amRNSChange of Adviser
29th Nov 200710:03 amRNSAGM Results
8th Nov 200712:38 pmRNSDirector/PDMR Shareholding
8th Nov 200712:34 pmRNSGlaucoma Device at AAO
31st Oct 20079:26 amRNSCompletion of Placing-Replace
31st Oct 20077:01 amRNSCompletion of Placing
26th Oct 20079:35 amRNSShareholder Approval
17th Oct 20072:21 pmRNSDirector/PDMR Shareholding
15th Oct 20079:23 amRNSCFO Appointment
25th Sep 200710:23 amRNSFurther Placing
24th Sep 20071:12 pmRNSFinal Results
24th Sep 20071:00 pmRNSFundraising
15th Aug 200712:43 pmRNSAIM Rule 26 Compliance
15th Aug 20079:27 amRNSFDA Approval for Truefield
2nd Jul 20077:01 amRNSNew Product Releases
29th Jun 200710:11 amRNSMaster License Agreement
22nd May 200711:15 amRNSLicensing agreement signed
8th May 20077:02 amRNSGlaucoma Device Demonstrated
28th Mar 20072:40 pmRNSInterim Results
14th Mar 200710:45 amRNSAward win for glaucoma device
12th Mar 20077:02 amRNSAddition to product released
19th Dec 200610:06 amRNSTotal Voting Rights
30th Nov 20068:27 amRNSAGM Statement
9th Nov 20067:01 amRNSGlaucoma Study Re-commences
2nd Nov 20067:01 amRNSNew Product
19th Oct 20065:38 pmRNSFinal Results - Replacement
19th Oct 200611:29 amRNSFinal Results
18th Oct 200611:04 amRNSDirectorate Change
17th Oct 20063:20 pmRNSNew Version of faceLAB
21st Sep 20064:41 pmRNSIssue of Equity
18th Sep 200611:24 amRNSAutomotive progress
18th Sep 20069:45 amRNSGlaucoma Grant Signed
30th Aug 200611:46 amRNSClinical Study Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.